SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Accentia Biopharmaceuticals Announces that FDA Grants Orphan Drug Status for Revimmune(TM) Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia